Ziconotide combination intrathecal therapy: Rationale and evidence

Clinical Journal of Pain

Volumn 26, Issue 7, 2010, Pages 635-644

  Wallace, Mark S ^a   Rauck, Richard L ^b   Deer, Timothy ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^c Center for Pain Relief   (United States)

Author keywords

chronic pain; combination therapy; intrathecal therapy; ziconotide

Indexed keywords

BACLOFEN; BUPIVACAINE; CLONIDINE; FENTANYL; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA; SUFENTANIL;

ANALGESIA; ANOREXIA; ANTINOCICEPTION; ANXIETY DISORDER; BLADDER DYSFUNCTION; CHRONIC PAIN; CLINICAL TRIAL; DEHYDRATION; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GAIT DISORDER; GASTROINTESTINAL MOTILITY; HALLUCINATION; HUMAN; HYPOTENSION; INTERMITTENT CATHETERIZATION; MONOTHERAPY; NAUSEA; NONHUMAN; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES; URINARY HESITANCY; VISUAL ANALOG SCALE; VOMITING;

EID: 77955985526     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e3181e017df     Document Type: Review

References (50)

1. Wallace M, Yaksh TL. Long-term spinal analgesic delivery: a review of the preclinical and clinical literature. Reg Anesth Pain Med. 2000;25:117-157.
2. Gilron I. Combination drug therapy for neuropathic pain. Eur J Pain. 2007;11(suppl 1):2.
3. Siddall PJ, Molloy AR, Walker S, et al. The efficacy of intrathecal morphine and clonidine in the treatment of pain after spinal cord injury. Anesth Analg. 2000;91:1493-1498.
4. Wang YX, Bezprozvannaya S, Bowersox SS, et al. Peripheral versus central potencies of N-type voltage-sensitive calcium channel blockers. Naunyn Schmiedebergs Arch Pharmacol. 1998;357:159-168.
5. Molinski TF, Dalisay DS, Lievens SL, et al. Drug development from marine natural products. Nat Rev Drug Discov. 2009; 8:69-85.
6. Wang YX, Gao D, Pettus M, et al. Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nocicep-tion in rats. Pain. 2000;84:271-281.
7. Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Annu Rev Pharmacol Toxicol. 1995;35:707-734.
8. Bowersox SS, Luther R. Pharmacotherapeutic potential of omega-conotoxin MVIIA (SNX-111), an N-type neuronal calcium channel blocker found in the venom of Conus magus. Toxicon. 1998;36:1651-1658.
9. PRIALTs [package insert]. South San Francisco, CA: Elan Pharmaceuticals, Inc; 2008.
10. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004;291:63-70.
11. Wallace MS, Charapata SG, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9:75-86.
12. Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal zicono-tide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393-406.
13. Deer T, Krames ES, Hassenbusch SJ, et al. Polyanalgesic Consensus Conference 2007: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2007;10:300-328.
14. Madaris L. Ziconotide: a non-opioid alternative for chronic neuropathic pain, a case report. SCI Nursing. 2008;25:19-23.
15. Saulino M. Successful reduction of neuropathic pain associated with spinal cord injury via of a combination of intrathecal hydromorphone and ziconotide: a case report. Spinal Cord. 2007;45:749-752.
16. Saulino M, Burton AW, Danyo DA, et al. Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. Eur J Phys Rehabil Med. 2009;45:61-67.
17. Wang YX, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Reviews. 2000;6:1-20.
18. Horvath G, Brodacz B, Holzer-Petsche U. Blood pressure changes after intrathecal co-administration of calcium channel blockers with morphine or clonidine at the spinal level. Naunyn Schmiedebergs Arch Pharmacol. 2002;366:270-275.
19. Webster LR, Fakata KL, Charapata S, et al. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving zicono-tide for severe chronic pain. Pain Med. 2008;9:282-290.
20. Wallace MS, Kosek PS, Staats P, et al. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. Pain Med. 2008;9:271-281.
21. Krakovsky AA, Bowie E. A retrospective analysis to determine the ideal ziconotide patient [abstract 109]. Pain Med. 2007;8: 91-92.
22. Stanton-Hicks M, Kapural L. An effective treatment of severe complex regional pain syndrome type 1 in a child using high doses of intrathecal ziconotide. J Pain Symptom Manage. 2006; 32:509-511.
23. Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures containing 25 mcg/mL ziconotide and 10mg/mL or 20 mg/mL morphine sulfate during simulated intrathecal administration. Int J Pharm Compounding. 2008;12:552-557.
24. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydro-morphone during simulated intrathecal administration. Neuromodulation. 2005;8:257-263.
25. Shields D, Montenegro R, Aclan J. Chemical stability of admixtures combining ziconotide with baclofen during simulated intrathecal administration. Neuromodulation. 2007;10 (suppl 1):12-17.
26. Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation. 2007;10(suppl 1):6-11.
27. Shields D, Montenegro R, Aclan J. Chemical stability of an admixture combining ziconotide and bupivacaine during simulated intrathecal administration. Neuromodulation. 2007; 10(suppl 1):1-5.
28. Shields DE, Aclan J, Szatkowski A. Chemical stability of admixtures combining ziconotide with fentanyl or sufentanil during simulated intrathecal administration. Int J Pharm Compounding. 2008;12:463-466.
29. Krames E. Implantable devices for pain control: spinal cord stimulation and intrathecal therapies. Best Pract Res Clin Anaesthesiol. 2002;16:619-649.
30. Pirec V, Laurito CE, Lu Y, et al. The combined effects of N-type calcium channel blockers and morphine on A delta versus C fiber mediated nociception. Anesth Analg. 2001;92: 239-243.
31. Lacy CF, Armstrong LL, Goldman MP, et al. Drug Information Handbook. 11th ed. Hudson, OH: Lexi-Comp; 2003.
32. Sakurada T, Komatsu T, Sakurada S. Mechanisms of nociception evoked by intrathecal high-dose morphine. Neuro-toxicology. 2005;26:801-809.
33. Deer T, Krames E, Hassenbusch S, et al. Management of intrathecal catheter-tip inflammatory masses: an updated 2007 consensus statement from an expert panel. Neuromodulation. 2008;11:77-91.
34. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer. 2001;9:84-96.
35. Canavero S, Bonicalzi V, Clemente M. No neurotoxicity from long-term (>5y) intrathecal infusion of midazolam in humans. J Pain Symptom Manage. 2006;32:1-3.
36. Kedlaya D, Reynolds L, Waldman S. Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol. 2002;16:651-665.
37. Kawamata T, Omote K, Yamamoto H, et al. Antihyperalgesic and side effects of intrathecal clonidine and tizanidine in a rat model of neuropathic pain. Anesthesiology. 2003;98: 1480-1483.
38. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy\a survey of clinical trends and decision making. J Pain Symptom Manage. 2000;20:S4-S11.
39. LIORESAL s [package insert]. Minneapolis, MN: Medtronic, Inc 2002.
40. Slonimski M, Abram SE, Zuniga RE. Intrathecal baclofen in pain management. Reg Anesth Pain Med. 2004;29: 269-276.
41. Bennett G, Burchiel K, Buchser E, et al. Clinical guidelines for intraspinal infusion: report of an expert panel. PolyAnalgesic Consensus Conference 2000. J Pain Symptom Manage. 2000;20: S37-S43.
42. Hassenbusch SJ, Portenoy RK, Cousins M, et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery-report of an expert panel. J Pain Symptom Manage. 2004;27:540-563.
43. Prager JP. Neuraxial medication delivery: the development and maturity of a concept for treating chronic pain of spinal origin. Spine. 2002;27:2593-2605.
44. Skov MJ, Beck JC, De Kater AW, et al. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Int J Toxicol. 2007;26:411-421.
45. Buchta T, Fakata K, Stuart W. Dilution and compounding of ziconotide for intrathecal administration. Int J Pharm Compounding. 2008;12:200-207.
46. PRIALT. New Drug Application N021060. San Diego, CA: Elan Pharmaceuticals, Inc; 2004.
47. Sabbe MB, Grafe MR, Pfeifer BL, et al. Toxicology of baclofen continuously infused into the spinal intrathecal space of the dog. Neurotoxicology. 1993;14:397-410.
48. Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med. 2007;8:259-262.
49. Murphy PM, Skouvaklis DE, Amadeo RJ, et al. Intrathecal catheter granuloma associated with isolated baclofen infusion. Anesth Analg. 2006;102:848-852.
50. Deer TR, Raso LJ, Coffey RJ, et al. Intrathecal baclofen and catheter tip inflammatory mass lesions (granulomas): a reevaluation of case reports and imaging findings in light of experimental, clinicopathological, and radiological evidence. Pain Med. 2008;9:391-395.